All In MedTech

Device Trial Radar · NCT04526938

Physician-modified Endovascular Graft for Repair of Complex Thoracoabdominal and Abdominal Aortic Aneurysms

Clinical Outcomes, Radiation Dosage, and Quality of Life in Patients Treated With Fenestrated Stent Grafts for Complex Thoracoabdominal and Abdominal Aortic Aneurysms, Thoracoabdominal Aortic Aneurysms Secondary to Aortic Dissections

Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Suspended

Status

Suspended

Enrollment

200

Planned (sponsor's estimate)

Start

Sep 20, 2021

Primary completion

Sep 2028

Study completion Sep 2028

Sponsor

Lead sponsor
Medstar Health Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 26, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the use of a physician-modified Cook Alpha Thoracic Endovascular Graft in the repair of complex aortic aneurysms and thoracoabdominal aortic aneurysms and aneurysms secondary to aortic dissections in high-risk patients having appropriate anatomy. The primary intent of the study is to assess the safety and preliminary effectiveness of the device. Additionally, the study will assess renal function, radiation exposure, and quality of life.

Conditions

  • Juxtarenal Aortic Aneurysm
  • Suprarenal Aortic Aneurysm
  • Thoracoabdominal Aortic Aneurysm

Interventions

  • Physician-Modified Cook Zenith Alpha Thoracic Endovascular GraftDevice

    Cook Zenith® Alpha Thoracic Endovascular Graft will be modified to allow for the maintenance of blood flow into the visceral and renal branch vessels.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Freedom from Major Adverse Events (MAE) at 30 daysTime frame: 30 days
  2. Proportion of study subjects with treatment success at 1 yearTime frame: 1 year
  3. Technical successTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.